The prediction for efficacy of gemcitabine postoperative adjuvant chemotherapy in pancreatic cancer by the expression analysis of the metabolic enzymes and transporters using LC-MS/MS Quantitative Targeted Proteomics
Not Applicable
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000006253
- Lead Sponsor
- Tohoku University Hepato-biliary pancreatic surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1. patients who administered non-curative resection (R2) 2. pancreatic cancer expect for invasive ductal carcinoma
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method overall survival, progression free survival, expression level of metabolic enzymes and transporters
- Secondary Outcome Measures
Name Time Method